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Abstract
Background: Optical coherence tomography (OCT) and magnetic resonance imaging (MRI) can pro-
vide complementary information on visual system damage in multiple sclerosis (MS).
Objectives: The objective of this paper is to determine whether a composite OCT/MRI score, reflecting
cumulative damage along the entire visual pathway, can predict visual deficits in primary progressive
multiple sclerosis (PPMS).
Methods: Twenty-five PPMS patients and 20 age-matched controls underwent neuro-ophthalmologic
evaluation, spectral-domain OCT, and 3T brain MRI. Differences between groups were assessed by
univariate general linear model and principal component analysis (PCA) grouped instrumental variables
into main components. Linear regression analysis was used to assess the relationship between low-
contrast visual acuity (LCVA), OCT/MRI-derived metrics and PCA-derived composite scores.
Results: PCA identified four main components explaining 80.69% of data variance. Considering each
variable independently, LCVA 1.25% was significantly predicted by ganglion cell-inner plexiform layer
(GCIPL) thickness, thalamic volume and optic radiation (OR) lesion volume (adjusted R2 0.328,
p¼ 0.00004; adjusted R2 0.187, p¼ 0.002 and adjusted R2 0.180, p¼ 0.002). The PCA composite score
of global visual pathway damage independently predicted both LCVA 1.25% (adjusted R2 value 0.361,
p¼ 0.00001) and LCVA 2.50% (adjusted R2 value 0.323, p¼ 0.00003).
Conclusion: A multiparametric score represents a more comprehensive and effective tool to explain
visual disability than a single instrumental metric in PPMS.
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Introduction
Impairment of visual acuity and retinal integrity
is frequent in patients with primary progressive
multiple sclerosis (PPMS) despite the absence of
episodes of acute optic neuritis (ON),1 suggesting
that they may be the consequence of primary
injury to retinal neurons, as part of the disease pro-
cess,2 or secondary damage related to anterior and
posterior visual pathway injury, with anterograde
and retrograde trans-synaptic degeneration being
known causes of retinal damage across different
pathologies.35
Among quantitative measures of visual acuity, low-
contrast visual acuity (LCVA), together with contrast
sensitivity, shows the greatest ability to capture
MS-related visual dysfunction,6 and it is associated
not only with optical coherence tomography
(OCT)-derived metrics of retinal integrity but also
with magnetic resonance imaging (MRI) measures
of damage involving both the anterior7 and post-
geniculate component of the visual pathway.710
Although OCT-derived metrics show stronger correl-
ation with LCVA than MR-derived metrics6 and
have been recently incorporated into MS clinical
trials,11 it remains to be determined whether a cumu-
lative index of visual pathway damage, including
MRI parameters, could be a better predictor of
visual disability than a single MRI or OCT param-
eter, offering a more comprehensive tool to explore
the physiopathology of VA deficits in PPMS.
Therefore, our aim was to investigate the correlation
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Twenty-five PPMS patients and 20 sex- and age-
matched controls (CTRLs) were prospectively
enrolled. Inclusion criteria for PPMS patients were
(1) age between 25 and 65 years, (2) an Expanded
Disability Status Scale (EDSS)12 lower than 6.5 at
screening visit, and (3) disease duration lower than
15 years. Exclusion criteria for all participants were
(1) neuropsychiatric disorders other than MS, (2)
ophthalmological pathologies (i.e. diabetes mellitus
or glaucoma), (3) history of alcohol or drug abuse,
and (4) contraindications to MRI. Demographic and
clinical data are summarized in Table 1.
Standard protocol approvals and patient consents
The study was approved by the local institutional
review board and written informed consent was
obtained from all participants.
Clinical assessment
VA was assessed as previously described.13 LCVA
scores at 2.50% and 1.25%6 were entered in the stat-
istical analysis.
Evaluation of visual pathway damage
Different metrics were computed in order to express
the damage occurring along the two main segments
constituting the visual pathway: the anterior path-
way, comprising the retina, optic nerves, chiasm,
and optic tracts; and the posterior pathway,
comprising the optic radiations and visual cortex,
connected by a single synapsis in the midbrain.
Damage of the first-order neuron, located in the
retina and projecting to the thalamic lateral genicu-
late nucleus (LGN), was evaluated through ganglion
cell-inner plexiform layer (GCIPL) thickness, retinal
nerve fiber layer (RNFL) thickness, optic nerve (ON)
and optic tract (OT) diameter measurements.
Damage of the second-order neuron, located in the
LGN and projecting to the visual cortex, was eval-
uated through thalamic volume (used as a proxy for
LGN volume), optic radiation (OR) volume and frac-
tional anisotropy (FA) measurements. Damage of the
third-order neuron, located in the visual cortex, was
evaluated through visual cortex volume and occipital
lobe cortical lesion (CL) count measurements.
OCT and MRI acquisition
Spectral-domain OCT imaging was performed using
Spectralis (Heidelberg Engineering, Heidelberg,
Germany; software version 5.6.eye explorer software
1.7.1.0) and processed as previously described.13
Scans that violated international consensus quality
control criteria (OSCAR-IB) were excluded from
the analysis.14,15 Both RNFL and GCIPL thickness
were evaluated and included in the statistical ana-
lysis as indirect structural markers of axonal and
neuronal damage.
MRI was performed using a 3.0 T scanner (Philips
Achieva, The Netherlands) with an eight-channel
sensitivity encoding (SENSE) phased-array head
coil. The MRI protocol included the following
sequences: (1) axial dual echo turbo spin echo;
(2) high-resolution sagittal three-dimensional (3D)
Table 1. Demographic and clinical characteristics of MS patients and controls.
PPMS (n¼ 25) CTRLs (n¼ 20) p value
Gender (male/female) 11/14 9/11 0.542a
Age (range), years 51.8 (3265) 51.1 (3463) 0.645b
Disease duration, years 8.7±4.8 
EDSS median (range) 4.0 (1.56.0) 
Letters read correctly at 100% 54±5 56±7 0.093
Letters read correctly at 2.5% 31±11 39±12 0.002
Letters read correctly at 1.25% 20±12 31±11 0.0001
MS: multiple sclerosis; PPMS: primary progressive multiple sclerosis; CTRLs: healthy controls; EDSS: Expanded
Disability Status Scale; SD: standard deviation.
Statistically significant p values are in bold.
aFisher’s exact test.
bMannWhitney test.
Unless otherwise specified, all values are expressed as mean±SD.
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T1-weighted turbo field echo; (3) twice-refocused
spin-echo echo planar imaging with b values of
1000 and 2000 s/mm2 and 30 directions each; and
(4) phase-sensitive inversion recovery.
MRI analysis
ON and OT diameters were measured as previously
described16 (e-Figure 1) and then normalized to head
size by multiplying the raw volumes by the SIENAX
scaling factor (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/
SIENA). Probabilistic tractography was performed
in order to reconstruct OR fibers using FMRIB
Diffusion Toolbox (FDT) from FSL (v5.0.8)
(http://www.fmrib.ox.ac.uk/fsl). Seed regions were
placed on the LGN and pericalcarine cortex; way-
point masks were drawn in the lateral wall of the
occipital horn of the lateral ventricles and exclusion
masks were drawn along the midline and anteriorly
to the Meyer’s loop. Brain T2 and T1 lesion volumes
(LVs) were measured as previously described.9 The
reconstructed OR tracts and the white matter (WM)
lesion regions of interest (ROIs) were used as masks
to calculate FA within ORs lesions and in OR
normal-appearing WM (NAWM), OR LV and OR
tract volume. OR LV was subtracted from the
mask-derived OR tract volume to obtain the final
OR tract volume measure. Normalized thalamic
volume, visual cortex volume and occipital lobe
CL count were assessed as previously described.13
Further details on the MRI protocol and tractography
procedure can be found in Supplemental Material
(e-Methods).
Statistical analysis
Data analysis was performed using SPSS 22.0
(SPSS, Chicago, IL, USA). Age and gender differ-
ences were tested with MannWhitney and Fisher’s
exact test. An analysis of variance was used to assess
between-group differences in terms of clinical, OCT
and MRI variables. Statistical significance was
defined as p< 0.05, Bonferroni corrected for mul-
tiple comparisons at p< 0.004. To avoid bias related
to strong inter-variable correlation, inter-eye average
of OCT metrics and left-right average of MRI met-
rics were entered in the principal component (PCA)
and regression analyses. A PCA was applied to OCT/
MRI variables and the components eigenvectors
were used to calculate a weighted value for the mea-
sured metrics and thus obtain a composite score for
each identified component and a global PCA-derived
score. Linear regression analyses were used to assess
binocular LCVA relationship with OCT/MRI-
derived metrics and PCA-derived composite scores.
Statistical significance was defined as p< 0.05,
Figure 1. PCA results. Segregation of OCT and MRI metrics in the four principal components with relative loadings. Each
variable is color coded. A larger dot indicates the maximum loading attributed to the specific variable from the PCA analysis.
PCA: principal component analysis; OCT: optical coherence tomography; MRI: magnetic resonance imaging; RNFL: retinal nerve
fiber layer; GCIPL: ganglion cellþ inner plexiform layer; ON: optic nerve; OT: optic tract; NAWM: normal-appearing white
matter; FA: fractional anisotropy; OR: optic radiation; WM: white matter; CL: cortical lesion.
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Bonferroni corrected for multiple comparisons at
p< 0.003.
Results
Patients’ OCT and MRI data are listed in Table 2.
Three out of the 50 MS eyes and two out of
40 CTRLs eyes were excluded from the analysis
because they did not fulfill the ophthalmological
criteria.
PCA of patients and controls’ OCT/MRI metrics
identified four components that explained 80.69%
of data variance. The first component, which gath-
ered all the variables pertaining to the anterior visual
pathway (RNFL thickness, GCIPL thickness, ON
and OT diameters, thalamic volume), explained
32.46% of data variance. The second component,
which included the visual cortex volume, explained
18.09% of data variance. The third component,
which gathered the OR LV and the occipital lobe
CL count, explained 15.26% of data variance. The
fourth component, which included variables describ-
ing the OR damage (OR NAWM FA, OR lesion FA,
OR LV), explained 14.88% of data variance. PCA
results are displayed in Figure 1.
Considering each variable independently, LCVA
1.25% was significantly predicted by GCIPL thick-
ness, thalamic volume and OR LV (adjusted
R2 0.328, p¼ 0.00004; adjusted R2 0.187, p¼ 0.002
and adjusted R2 0.180, p¼ 0.002, Bonferroni cor-
rected). Additional results of the regression analysis
for each individual metric are reported in Table 3.
The PCA composite score of global visual pathway
damage independently predicted both LCVA 1.25%
(adjusted R2 value 0.361, p¼ 0.00001, Bonferroni
corrected) and LCVA 2.50% (adjusted R2 value
0.323, p¼ 0.00003, Bonferroni corrected).
Among the single-component-derived composite
scores, only the anterior visual pathway score signifi-
cantly predicted LCVA 1.25% (adjusted R2 value
0.361, p¼ 0.00001, Bonferroni corrected) and
LCVA 2.5% (adjusted R2 value 0.321, p¼ 0.00004,
Bonferroni corrected), while the OR damage score,
the lesion load score and the visual cortex score were
not predictive of LCVA 1.25% (adjusted R2 value
0.006, p¼ 0.388; adjusted R2 value 0.007,
p¼ 0.405 and adjusted R2 value 0.053, p¼ 0.071,
respectively) and LCVA 2.50% (adjusted R2 value
0.015, p¼ 0.556; adjusted R2 value 0.012,
p¼ 0.487 and adjusted R2 value 0.041, p¼ 0.099,
respectively).
Discussion
Our results show that an MRI- and OCT-based multi-
parametric measure can predict VA deficits more
effectively than single OCT- and MRI-derived
Table 2. OCT and MR parameters in PPMS and CTRLs.
PPMS (n¼ 25) CTRLs (n¼ 20) p value
RNFL (mm) 86.9±13.6 92.8±12.4 0.040
GCIPL (mm) 66.0±9.4 72.6±6.7 0.001
ON diameter (mm) 6.0±0.7 6.2±0.6 0.255
OT diameter (mm) 5.3±0.7 5.8±0.8 0.021
Thalamic volume (ml) 8.89±1.12 10.11±0.92 0.001
OR volume (ml) 1.51±0.38 1.66±0.33 0.168
OR NAWM FAa 0.44±0.04 0.47±0.03 0.003
OR lesion volume (ml) 0.10±0.10  
OR WM lesion FAa 0.37±0.06  
Visual cortex signal intensityb 0.34±0.06 0.39±0.05 0.011
Occipital lobe CL count 0.43±0.78  
OCT: optical coherence tomography; MRI: magnetic resonance imaging; PPMS: primary progressive multiple scler-
osis; CTRLs: healthy controls; RNFL: retinal nerve fiber layer; GCIPL: ganglion cellþ inner plexiform layer; ON:
optic nerve; OT: optic tract; OR: optic radiation; WM: white matter; NAWM: normal-appearing white matter; FA:
fractional anisotropy; OR: optic radiation; CL: cortical lesion; SD: standard deviation.
Statistically significant p values are in bold.
aFractional anisotropy value (adimensional) extracted from white matter region of interest.
bSignal intensity values (adimensional eigenvalues) extracted from gray matter region of interest.
Unless specified, all values are expressed as mean±SD.
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metrics of visual pathway damage. The global visual
pathway score and the anterior visual pathway score
showed a similar predictive power in the regression
analysis, suggesting that the damage of the anterior
visual pathway plays a prominent role in determining
visual disability. Even if only a few of the single
metric regressions survived the correction for mul-
tiple comparisons, the predictive trends highlighted
by this analysis deserve a comment. With respect to
the anterior visual pathway, the metrics associated
with VA were the GCIPL thickness, in line with
previous findings,10 and the thalamic volume. The
predictive role of the thalamus might be related to
its central position along the visual pathway that
makes it susceptible both to anterograde and retro-
grade trans-synaptic neurodegeneration from ana-
tomically connected structures, although the
development of thalamic atrophy might partially
derive from the neurodegenerative component of
the disease that also drives global brain atrophy
development. With respect to the posterior visual
pathway, only OR lesion volume was correlated
with visual deficit. Although this is a little surprising
because of the general paucity of WM inflammatory
lesions and predominance of gray matter (GM) path-
ology in PPMS, it might be partially explained by the
small number of CLs detected in the occipital lobe of
our patients. In addition, the low contribute of visual
cortex volume to visual disability might be
explained, at least in part, by the fact that damage
to the visual cortex has been primarily reported as a
consequence of anterograde degeneration secondary
to optic neuritis,10 which none of our patients had
experienced. On the other hand, the lack of clinically
evident episodes of optic neuritis does not exclude
the presence of anterior visual pathway damage in
our cohort that is indeed suggested by the results of
our regression analysis.
Other groups have reported that visual dysfunction is
related to retinal layer thinning17 and damage of
ORs9 even in patients with PPMS. However, the
use of a composite score including both OCT- and
MRI-derived metrics of tissue damage can increase
our understanding of the physiopathology of VA def-
icits in PPMS and provide a measure to better moni-
tor their evolution.
Since each instrumental metric refers to different MS
pathological aspects, diverse measures provide com-
plementary information on the contemporaneous
involvement of various structures of the same func-
tional system. As a consequence, a composite index
provides a better correlate for MS pathological pro-
cess and its relation to clinical disability, increasing
the predictive value of the measure even in small
populations.
Although our composite measure was a good pre-
dictor of visual disability, it could be further improved
by the inclusion of other indices of microstructural
damage (i.e. magnetization transfer ratio (MTR)
within the visual cortex, ONs and OTs) and would
benefit from a validation in a larger MS population.
Table 3. Regression analysis between LCVA and OCT/MRI metrics.
LCVA 2.50% LCVA 1.25%
Adjusted R2 p value Adjusted R2 p value
RNFL 0.057 0.064 0.165 0.004
GCIPL 0.156 0.005 0.328 0.00004
ON diameter 0.011 0.475 0.016 0.573
OT diameter 0.006 0.395 0.012 0.226
Thalamic volume 0.096 0.023 0.187 0.002
OR volume 0.029 0.139 0.021 0.172
OR NAWM FA 0.055 0.069 0.079 0.036
OR lesion volume 0.157 0.005 0.180 0.002
OR WM lesion FA 0.157 0.058 0.156 0.059
Visual cortex signal intensity 0.049 0.081 0.061 0.059
Occipital lobe CL count 0.019 0.649 0.015 0.560
LCVA: low-contrast visual acuity; OCT: optical coherence tomography; MRI: magnetic resonance imaging; RNFL:
retinal nerve fiber layer; GCIPL: ganglion cellþ inner plexiform layer; ON: optic nerve; OT: optic tract; OR: optic
radiation; WM: white matter; NAWM: normal-appearing white matter; FA: fractional anisotropy; OR: optic radiation;
CL: cortical lesion.
Statistically significant p values are in bold.
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In particular, considering our small sample size and
the consequent risk for overfitting of the model, the
replication of our findings in other datasets would
increase the external validity of our results.
In summary, our study provides evidence that, simi-
larly to what has been reported for motor disability,18
a multiparametric score based on different instru-
mental metrics can explain more comprehensively
visual dysfunction rather than a single parameter,
since it includes indicators of different MS patho-
logical processes that contribute to clinical deficit.
Acknowledgements
The authors thank Drs M. Fabian, C. Riley and S.
Krieger for patient referrals; Dr A. Harel for help
with cortical lesion assessment; Drs P. Calabresi
and J. Button for help with the OCT metrics assess-
ment and Yadira Bencosme and Colleen Farrell for
help with patient scheduling and assistance.
Author contributions are as follows: MI had full
access to all the data in the study and takes respon-
sibility for the integrity of the data and the accuracy
of the data analysis. Study concept and design: MI
and MP. Acquisition, analysis, or interpretation of
data: all authors. Drafting of the manuscript: VP,
MP, CS and MI. Critical revision of the manuscript
for important intellectual content: all authors.
Statistical analysis: VP, MP and MI. Obtained fund-
ing: MI. Study supervision: MI.
Conflicts of interest
The author(s) declared the following potential con-
flicts of interest with respect to the research, author-
ship, and/or publication of this article: Dr Valentina
Poretto has nothing to disclose. Dr Maria Petracca
received a research fellowship from Fondazione
Italiana Sclerosi Multipla (2013/B/7). Dr Catarina
Saiote has nothing to disclose. Dr Enricomaria
Mormina has nothing to disclose. Dr Jonathan
Howard has received royalties from Demos-
Springer publishing and Up-To-Date. Dr Aaron
Miller has served as a consultant and/or participant
in advisory board meetings for Genzyme/Sanofi-
Aventis, Biogen Idec, Glaxo Smith Kline, EMD
Serono (Merck Serono), Novartis, ONO, Acorda,
Nuron Biotech, Teva, Questcor and Accordant
Health Services. He has received research support
from Acorda, Novartis, Genentech, Genzyme/
Sanofi-Aventis, Biogen Idec, Roche and Questcor.
He has served as editor of Continuum, a continuing
medical education publication of the American
Academy of Neurology (AAN), and currently
serves as editor of Continuum Audio. He is a
member of the editorial board of Multiple Sclerosis
and Related Disorders. He occasionally performs
expert reviews of medical records or serves as an
expert witness in medical malpractice cases. Dr
Fred Lublin discloses the following sources of fund-
ing for research: Acorda Therapeutics Inc, Biogen
Idec, Novartis Pharmaceuticals Corp, Teva
Neuroscience Inc, Genzyme, Sanofi, Celgene, the
National Institutes of Health (NIH); the National
Multiple Sclerosis Society (NMSS); consulting
agreements/advisory boards/data and safety monitor-
ing board (DSMB): Bayer HealthCare
Pharmaceuticals, Biogen Idec, EMD Serono Inc,
Novartis, Teva Neuroscience, Actelion, Sanofi-
Aventis, Acorda, Questcor, Roche, Genentech,
Celgene, Johnson & Johnson, Revalesio, Coronado
Bioscience, Genzyme, MedImmune, Bristol-Myers
Squibb, Xenoport, Receptos and Forward Pharma;
co-chief editor: Multiple Sclerosis and Related
Diseases; and stock ownership: Cognition
Pharmaceuticals Inc. Dr Matilde Inglese has received
research grants from the NIH, NMSS), Novartis
Pharmaceuticals Corp., and Teva Neuroscience.
Funding
The author(s) disclosed receipt of the following
financial support for the research, authorship, and/
or publication of this article: This study was sup-
ported, in part, by Novartis Pharmaceuticals
(CFTY20DUSNC15T) and the National Multiple
Sclerosis Society (NMSS RG 5120A3/1).
Supplementary material




1. Pulicken M, Gordon-Lipkin E, Balcer LJ, et al. Optical
coherence tomography and disease subtype in multiple
sclerosis. Neurology 2007; 69: 20852092.
2. Green AJ, McQuaid S, Hauser SL, et al. Ocular path-
ology in multiple sclerosis: Retinal atrophy and inflam-
mation irrespective of disease duration. Brain 2010;
133: 15911601.
3. Evangelou N, Konz D, Esiri MM, et al. Size-selective
neuronal changes in the anterior optic pathways suggest
a differential susceptibility to injury in multiple scler-
osis. Brain 2001; 124(Pt 9): 18131820.
4. Gupta N, Ly T, Zhang Q, et al. Chronic ocular hyper-
tension induces dendrite pathology in the lateral gen-
iculate nucleus of the brain. Exp Eye Res 2007; 84:
176184.
Multiple Sclerosis Journal—Experimental, Translational and Clinical
6 www.sagepub.com/msjetc
5. Jindahra P, Petrie A and Plant GT. Retrograde trans-
synaptic retinal ganglion cell loss identified by optical
coherence tomography. Brain 2009; 132: 628634.
6. Fisher JB, Jacobs DA, Markowitz CE, et al. Relation
of visual function to retinal nerve fiber layer thickness
in multiple sclerosis. Ophthalmology 2006; 113:
324332.
7. Kolbe SC, Marriott M, van der Walt A, et al. Diffusion
tensor imaging correlates of visual impairment in mul-
tiple sclerosis and chronic optic neuritis. Investig
Ophthalmol Vis Sci 2012; 53: 825832.
8. Wu GF, Schwartz ED, Lei T, et al. Relation of vision
to global and regional brain MRI in multiple sclerosis.
Neurology 2007; 69: 21282135.
9. Reich DS, Smith S, Gordon-Lipkin E, et al. Damage to
the optic radiation in multiple sclerosis is associated
with retinal injury and visual disability. Arch Neurol
2009; 66: 9981006.
10. Audoin B, Fernando KTM, Swanton JK, et al.
Selective magnetization transfer ratio decrease in the
visual cortex following optic neuritis. Brain 2006;
129: 10311039.
11. Balcer LJ. Clinical trials to clinical use: Using vision
as a model for multiple sclerosis and beyond.
J Neuroophthalmol 2014; 34(Suppl): S18S23.
12. Kurtzke JF. Rating neurologic impairment in multiple
sclerosis: An Expanded Disability Status Scale
(EDSS). Neurology 1983; 33: 14441452.
13. Petracca M, Cordano C, Cellerino M, et al. Retinal
degeneration in primary-progressive multiple scler-
osis: A role for cortical lesions? Mult Scler 2017;
23: 4350.
14. Tewarie P, Balk L, Costello F, et al. The OSCAR-IB
consensus criteria for retinal OCT quality assessment.
PLoS One 2012; 7: 17.
15. Schippling S, Balk L, Costello F, et al. Quality control
for retinal OCT in multiple sclerosis: Validation of the
OSCAR-IB criteria. Mult Scler 2015; 21: 163170.
16. Schmitz B, Schaefer T, Krick CM, et al. Configuration
of the optic chiasm in humans with albinism as
revealed by magnetic resonance imaging. Investig
Ophthalmol Vis Sci 2003; 44: 1621.
17. Oberwahrenbrock T, Schippling S, Ringelstein M,
et al. Retinal damage in multiple sclerosis disease sub-
types measured by high-resolution optical coherence
tomography. Mult Scler Int 2012; 2012: 530305.
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